| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8796318 | CELGENE INTL | Modulators of sphingosine phosphate receptors |
May, 2029
(5 years from now) | |
| US8481573 | CELGENE INTL | Modulators of sphingosine phosphate receptors |
May, 2029
(5 years from now) | |
| US11680050 | CELGENE INTL | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof |
Sep, 2038
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9382217 | CELGENE INTL | Modulators of sphingosine phosphate receptors |
May, 2029
(5 years from now) | |
| US10239846 | CELGENE INTL | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Nov, 2030
(6 years from now) | |
Zeposia is owned by Celgene Intl.
Zeposia contains Ozanimod Hydrochloride.
Zeposia has a total of 5 drug patents out of which 0 drug patents have expired.
Zeposia was authorised for market use on 25 March, 2020.
Zeposia is available in capsule;oral dosage forms.
Zeposia can be used as indicated for the treatment of moderately to severely active ulcerative colitis, treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults, treatment of moderately to severely active ulcerative colitis (uc) in adults.
Drug patent challenges can be filed against Zeposia from 25 March, 2024.
The generics of Zeposia are possible to be released after 30 September, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 25, 2025 |
| New Indication(I-860) | May 27, 2024 |
Drugs and Companies using OZANIMOD HYDROCHLORIDE ingredient
NCE-1 date: 25 March, 2024
Market Authorisation Date: 25 March, 2020
Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Indicated for the tr...
Dosage: CAPSULE;ORAL
ZEPOSIA family patents
